INTRODUCTION:
To contain the COVID-19 pandemics, vaccines have been developed and are being administered worldwide. The SARS-CoV-2 m-RNA vaccine Comirnaty (BNT162b2, BioNTech/Pfizer) is a gene-therapy-based vaccine, whose long-term effects are inevitably unknown and need therefore to be intensively studied.1,2
BNT162b2 vaccine has been described to up-regulate Th1-cell response, incrementing inflammatory cytokines involved in the pathogenesis of autoimmune diseases, including connective tissue diseases, psoriasis, vitiligo and lichen planus (LP).1-3
Currently only two cases of LP following COVID-19 vaccination, and one lichenoid drug eruption (LDE), have been described.3-5